Translating Glutamate: From Pathophysiology to Treatment

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821 · see citing works

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · see citing works

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · see citing works

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · see citing works

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · see citing works

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · see citing works

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · see citing works

The Neural Basis of Addiction: A Pathology of Motivation and Choice

Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757 · see citing works

Drug Addiction and Its Underlying Neurobiological Basis: Neuroimaging Evidence for the Involvement of the Frontal Cortex

Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667 · see citing works

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020 · see citing works

Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia

Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., Nord, A. S., Kusenda, M., Malhotra, D., Bhandari, A., et al. (2008) · Science · doi:10.1126/science.1155174 · Cited by 1,800 · see citing works

The glutamate homeostasis hypothesis of addiction

Kalivas, P. W. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2515 · Cited by 1,350 · see citing works

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · see citing works

Relationship Between Dopamine D ₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090 · see citing works

Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P. A., Kavvoura, F. K., Khoury, M. J., Tanzi, R. E., & Bertram, L. (2008) · Nature Genetics · doi:10.1038/ng.171 · Cited by 1,054 · see citing works

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · see citing works

Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats

Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006 · see citing works

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · see citing works

Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting

Betancur, C. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.078 · Cited by 954 · see citing works

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894 · see citing works

Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors

Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750889.x · Cited by 883 · see citing works

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · see citing works

Metabotropic glutamate receptors: electrophysiological properties and role in plasticity

Anwyl, R. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00050-2 · Cited by 776 · see citing works

Mismatch negativity in schizophrenia: a meta-analysis

Umbricht, D., & Krljes, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.002 · Cited by 742 · see citing works

Drug Seeking Becomes Compulsive After Prolonged Cocaine Self-Administration

Vanderschuren, L. J. M. J., & Everitt, B. J. (2004) · Science · doi:10.1126/science.1098975 · Cited by 733 · see citing works

Metabotropic glutamate receptors: Synaptic transmission, modulation, and plasticity

Nakanishi, S. (1994) · Neuron · doi:10.1016/0896-6273(94)90043-4 · Cited by 716 · see citing works

Unveiling the Functions of Presynaptic Metabotropic Glutamate Receptors in the Central Nervous System

Schoepp, D. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29296-x · Cited by 693 · see citing works

Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression

aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690 · see citing works

Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia.

Javitt, D. C., Steinschneider, M., Schroeder, C. E., & Arezzo, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11962 · Cited by 662 · see citing works

Functional connectivity density mapping

Tomasi, D. G., & Volkow, N. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001414107 · Cited by 646 · see citing works

Epigenetic Modification of the <i>FMR1</i> Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · see citing works

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607 · see citing works

Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression

Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · see citing works

The Autistic Neuron: Troubled Translation?

Kelleher, R. J., & Bear, M. F. (2008) · Cell · doi:10.1016/j.cell.2008.10.017 · Cited by 598 · see citing works

Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly

Sheline, Y. I., Raichle, M. E., Snyder, A. Z., Morris, J. C., Head, D., Wang, S., & Mintun, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.024 · Cited by 597 · see citing works

Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers

Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 583 · see citing works

The Mismatch Negativity

Näätänen, R. (1995) · Ear and Hearing · doi:10.1097/00003446-199502000-00002 · Cited by 572 · see citing works

The Glutamatergic Dysfunction Hypothesis for Schizophrenia

Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · see citing works

GABA Neurons and the Mechanisms of Network Oscillations: Implications for Understanding Cortical Dysfunction in Schizophrenia

González‐Burgos, G., & Lewis, D. A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn070 · Cited by 568 · see citing works

Autism spectrum disorders-a genetics review

Miles, J. H. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3181ff67ba · Cited by 567 · see citing works

Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions

Javitt, D. C. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 563 · see citing works

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients

Nordström, A., Farde, L., Wiesel, F., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527 · see citing works

Glutamate as a therapeutic target in psychiatric disorders

Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524 · see citing works

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

Preskorn, S., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 522 · see citing works

Excitatory Amino Acid Neurotransmission: NMDA Receptors and Hebb-Type Synaptic Plasticity

Cotman, C. W., & Monaghan, D. T. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000425 · Cited by 484 · see citing works

Amplitude of low-frequency oscillations in schizophrenia: A resting state fMRI study

Hoptman, M. J., Zuo, X., Butler, P. D., Javitt, D. C., D’Angelo, D., Mauro, C. J., & Milham, M. P. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.030 · Cited by 463 · see citing works

Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus

Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.027 · Cited by 454 · see citing works

Modulation of N -methyl- d -aspartate receptor function by glycine transport

Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 412 · see citing works

Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients

Light, G. A., & Braff, D. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.127 · Cited by 407 · see citing works

N-Acetylcysteine reverses cocaine-induced metaplasticity

Moussawi, K., Pacchioni, A. M., Moran, M., Olive, M. F., Gass, J. T., Lavı́n, A., & Kalivas, P. W. (2009) · Nature Neuroscience · doi:10.1038/nn.2250 · Cited by 400 · see citing works

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?

Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 397 · see citing works

Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine Seeking

Knackstedt, L. A., Meléndez, R. I., & Kalivas, P. W. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.018 · Cited by 396 · see citing works

Redox dysregulation, neurodevelopment, and schizophrenia

Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384 · see citing works

Glutamate-based antidepressants: 20 years on

Skolnick, P., Popik, P., & Trullás, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 382 · see citing works

Transition to Addiction Is Associated with a Persistent Impairment in Synaptic Plasticity

Kasanetz, F., Deroche‐Gamonet, V., Berson, N., Balado, É., Lafourcade, M., Manzoni, O. J., & Piazza, P. V. (2010) · Science · doi:10.1126/science.1187801 · Cited by 364 · see citing works

Children and adolescents with autism exhibit reduced MEG steady-state gamma responses

Wilson, T. W., Rojas, D. C., Reite, M. L., Teale, P. D., & Rogers, S. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.002 · Cited by 350 · see citing works

Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior

Basu, A. C., Tsai, G. E., Ma, C.-L., Ehmsen, J. T., Mustafa, A. K., Han, L., Jiang, Z. I., Benneyworth, M. A., Froimowitz, M., LANGE, N. D., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.130 · Cited by 340 · see citing works

Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Linderholm, K., Skogh, E., Olsson, S., Dahl, M., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia bulletin · doi:10.1093/schbul/sbq086 · Cited by 335 · see citing works

A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia

Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., DEMIRANDA, J., Wolosker, H., & Agam, G. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.010 · Cited by 323 · see citing works

Resting Brain Connectivity: Changes during the Progress of Alzheimer Disease

Zhang, H.-Y., Wang, S.-J., Liu, B., Ma, Z.-L., Yang, M., Zhang, Z.-J., & Teng, G.-J. (2010) · Radiology · doi:10.1148/radiol.10091701 · Cited by 320 · see citing works

Validating γ oscillations and delayed auditory responses as translational biomarkers of autism

Gandal, M. J., Edgar, J. C., Ehrlichman, R. S., Mehta, M., Roberts, T. P. L., & Siegel, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.031 · Cited by 314 · see citing works

Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia

Sweet, R. A., Henteleff, R. A., Zhang, W., Sampson, A. R., & Lewis, D. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.67 · Cited by 290 · see citing works

Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine

Salvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277 · see citing works

Glutamatergic and resting state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula

Horn (2010) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2010.00033 · Cited by 276 · see citing works

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272 · see citing works

The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behaviors in Rats

Cartmell, J., Monn, J. A., & Schoepp, D. D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35084-0 · Cited by 270 · see citing works

Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis

Tsai, G. E., & Lin, P. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269 · see citing works

MODEL PSYCHOSES AND SCHIZOPHRENIA

Luby, E. D., Gottlieb, J. S., Cohen, B. D., Rosenbaum, G., & Domino, E. F. (1962) · American Journal of Psychiatry · doi:10.1176/ajp.119.1.61 · Cited by 268 · see citing works

Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267 · see citing works

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging

Howes, O. D., Egerton, A., Allan, V., McGuire, P., Stokes, P. R. A., & Kapur, S. (2009) · Current pharmaceutical design · doi:10.2174/138161209788957528 · Cited by 261 · see citing works

The Role of Cystine-Glutamate Exchange in Nicotine Dependence in Rats and Humans

Knackstedt, L. A., LaRowe, S., Mardikian, P., Malcolm, R., Upadhyaya, H., Hedden, S., Markou, A., & Kalivas, P. W. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.040 · Cited by 260 · see citing works

Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome

Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259 · see citing works

How specific are deficits in mismatch negativity generation to schizophrenia?

Umbricht, D., Koller, R., Schmid, L., Skrabo, A., Grübel, C., Huber, T., & Stassen, H. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01642-6 · Cited by 247 · see citing works

NMDA receptors and schizophrenia

Kristiansen, L. V., Huerta, I., BENEYTO, M., & Meador‐Woodruff, J. H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.013 · Cited by 243 · see citing works

Reduced Interhemispheric Resting State Functional Connectivity in Cocaine Addiction

Kelly, C. A. M., Zuo, X., Gotimer, K., Cox, C. L., Lynch, L. K., Brock, D. C., Imperati, D., Garavan, H., Rotrosen, J., Castellanos, F. X., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.022 · Cited by 231 · see citing works

White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosis

Karlsgodt, K. H., Niendam, T. A., Bearden, C. E., & Cannon, T. D. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.03.013 · Cited by 229 · see citing works

Neuropsychiatric applications of DTI – a review

Lim, K. O., & Helpern, J. A. (2002) · NMR in Biomedicine · doi:10.1002/nbm.789 · Cited by 226 · see citing works

N-Acetylcysteine Reduces Extinction Responding and Induces Enduring Reductions in Cue- and Heroin-Induced Drug-Seeking

Zhou, W., & Kalivas, P. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.008 · Cited by 225 · see citing works

Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine

Salvadore, G., Cornwell, B. R., Sambataro, F., Latov, D. R., Colon-Rosario, V., Carver, F. W., Holroyd, T., Diazgranados, N., Machado‐Vieira, R., Grillon, C., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.24 · Cited by 217 · see citing works

LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress

Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B. L., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207 · see citing works

Cocaine self-administration selectively abolishes LTD in the core of the nucleus accumbens

Martín, M., Chen, B. T., Hopf, F. W., Bowers, M. S., & Bonci, A. (2006) · Nature Neuroscience · doi:10.1038/nn1713 · Cited by 205 · see citing works

Upregulation of Glt1 Attenuates Cue-Induced Reinstatement of Cocaine-Seeking Behavior in Rats

Sari, Y., Smith, K. D., Ali, P. K., & Rebec, G. V. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1746-09.2009 · Cited by 200 · see citing works

Auditory event-related potential abnormalities in bipolar disorder and schizophrenia

O'Donnell, B. F., Vohs, J. L., Hetrick, W. P., Carroll, C. A., & Shekhar, A. (2004) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2004.02.001 · Cited by 190 · see citing works

Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia

Madeira, C., Freitas, M. E., Vargas-Lopes, C., Wolosker, H., & Panizzutti, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.002 · Cited by 190 · see citing works

Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia

Wonodi, I., & Schwarcz, R. M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190 · see citing works

Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist

Phelps, L. E., Brutsché, N. E., Moral, J. R., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.029 · Cited by 188 · see citing works

Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model

Labrie, V., Fukumura, R., Rastogi, A., Fick, L. J., Wang, W., Boutros, P. C., Kennedy, J. L., Semeralul, M. O., Lee, F. H., Baker, G. B., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp261 · Cited by 185 · see citing works

Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

Dunayevich, E., Erickson, J., Levine, L. R., Landbloom, R. P., Schoepp, D. D., & Tollefson, G. D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301531 · Cited by 180 · see citing works

Fragile X: Leading the Way for Targeted Treatments in Autism

Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176 · see citing works

Glutamate receptors in extinction and extinction-based therapies for psychiatric illness

Myers, K. M., Carlezon, W., & Davis, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.88 · Cited by 175 · see citing works

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia

Verrall, L., Burnet, P. W. J., Betts, J. F., & Harrison, P. J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.99 · Cited by 171 · see citing works

In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats

Battaglia, G., Monn, J. A., & Schoepp, D. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00442-4 · Cited by 163 · see citing works

Intracortical Mechanisms of Mismatch Negativity Dysfunction in Schizophrenia

Javitt, D. C. (2000) · Audiology and Neurotology · doi:10.1159/000013882 · Cited by 161 · see citing works

Ketamine Produces Lasting Disruptions in Encoding of Sensory Stimuli

Maxwell, C. R., Ehrlichman, R. S., Liang, Y., Trief, D., Kanes, S., Karp, J. D., & Siegel, S. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.091199 · Cited by 160 · see citing works

Mismatch negativity in children with autism and typical development

Dunn, M. A., Gomes, H., & Gravel, J. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0359-3 · Cited by 159 · see citing works

Mismatch Negativity in Aging and in Alzheimer’s and Parkinson’s Diseases

Pekkonen, E. (2000) · Audiology and Neurotology · doi:10.1159/000013883 · Cited by 157 · see citing works

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2099-9 · Cited by 156 · see citing works

Deviance-elicited Changes in Event-related Potentials are Attenuated by Ketamine in Mice

Ehrlichman, R. S., Maxwell, C. R., Majumdar, S., & Siegel, S. J. (2008) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2008.20097 · Cited by 154 · see citing works

1H-MRS at 4 Tesla in minimally treated early schizophrenia

Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153 · see citing works

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis

Heekeren, K., Daumann, J., Neukirch, A., Stock, C., Kawohl, W., Norra, C., Waberski, T. D., & Gouzoulis‐Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1129-4 · Cited by 152 · see citing works

The Effects of a Sub-Anaesthetic Dose of Ketamine on Human Selective Attention

Oranje, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00118-9 · Cited by 147 · see citing works

Effect of ketamine on the neuromagnetic mismatch field in healthy humans

Kreitschmann‐Andermahr, I., Rosburg, T., Demme, U., Gaser, E., Nowak, H., & Sauer, H. (2001) · Cognitive Brain Research · doi:10.1016/s0926-6410(01)00043-x · Cited by 144 · see citing works

Molecular Genetics of Addiction and Related Heritable Phenotypes

Uhl, G. R., Drgon, T., Johnson, C., Li, C., Contoreggi, C. S., Hess, J., Naiman, D. Q., & Liu, Q. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.018 · Cited by 139 · see citing works

Candidate Electrophysiological Endophenotypes of Hyper-Reactivity to Change in Autism

Gomot, M., Blanc, R., Cléry, H., Roux, S., Barthélémy, C., & Bruneau, N. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1091-y · Cited by 137 · see citing works

The Emerging Link Between Autoimmune Disorders and Neuropsychiatric Disease

Kayser, M. S., & Dalmau, J. (2011) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.23.1.90 · Cited by 133 · see citing works

Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats

Tikhonravov, D. L., Neuvonen, T., Pertovaara, A., Savioja, K., Ruusuvirta, T., Näätänen, R., & Carlson, S. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.006 · Cited by 131 · see citing works

Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine

Hashimoto, K., Fujita, Y., Horio, M., Kunitachi, S., Iyo, M., Ferraris, D. V., & Tsukamoto, T. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.002 · Cited by 128 · see citing works

Diffusion based abnormality markers of pathology: Toward learned diagnostic prediction of ASD

Ingalhalikar, M., Parker, D., Bloy, L., Roberts, T. P. L., & Verma, R. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.05.023 · Cited by 121 · see citing works

Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders

Machado‐Vieira, R., Salvadore, G., Ibrahim, L. A., Diazgranados, N., & Zarate, C. A. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168010 · Cited by 117 · see citing works

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice

Linden, A.-M., Shannon, H. E., Baez, M., Yu, J., Koester, A., & Schoepp, D. D. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2098-x · Cited by 117 · see citing works

Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology

DeVito, L. M., Balu, D. T., Kanter, B. R., Lykken, C., Basu, A. C., COYLE, J. T., & Eichenbaum, H. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00656.x · Cited by 114 · see citing works

Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice?

Umbricht, D., Vyssotki, D., Латанов, А. В., Nitsch, R. M., & Lipp, H. (2004) · Clinical Neurophysiology · doi:10.1016/j.clinph.2004.08.015 · Cited by 112 · see citing works

Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients

Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L., & Iyo, M. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-6 · Cited by 106 · see citing works

Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders

Zarate, C. A., Quiroz, J. A., Quiroz, J. A., Manji, H. K., Payne, J. L., Kornstein, S. G., Manji, A. H. K., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4204 · Cited by 104 · see citing works

Glycine Therapy of Schizophrenia

Waziri, R. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90093-5 · Cited by 100 · see citing works

Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?

Schoepp, D. D., & Marek, G. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606177 · Cited by 100 · see citing works

Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors

Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 99 · see citing works

Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats

Meloni, D., Gambarana, C., Montis, M. G. D., Pra, P. D., Taddei, I., & Tagliamonte, A. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90374-3 · Cited by 96 · see citing works

Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.

Javitt, D. C. (2009) · PubMed · Cited by 94 · see citing works

Antagonism of phencyclidine-induced hyperactivity by glycine in mice

Tóth, E., & Lajtha, Á. (1986) · Neurochemical Research · doi:10.1007/bf00965013 · Cited by 94 · see citing works

Schizophrenia: Moving Beyond Monoamine Antagonists

Conn, P. J., Tamminga, C. A., Schoepp, D. D., & Lindsley, C. W. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.7 · Cited by 84 · see citing works

Effects of the NMDA receptor antagonist ketamine on flavor memory: Conditioned aversion, latent inhibition, and habituation of neophobia

Aguado, L., Antonio, A. S., Pérez, L., del Valle, R., & Gómez, J. (1994) · Behavioral and Neural Biology · doi:10.1016/s0163-1047(05)80010-x · Cited by 80 · see citing works

Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP)

Javitt, D. C., Jayachandra, M., Lindsley, R. W., Specht, C. M., & Schroeder, C. E. (2000) · Clinical Neurophysiology · doi:10.1016/s1388-2457(99)00313-2 · Cited by 79 · see citing works

Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-d-aspartate receptor complex

Skolnick, P., Miller, R. L., Young, A. J., Boje, K. M. K., & Trullás, R. (1992) · Psychopharmacology · doi:10.1007/bf02245261 · Cited by 78 · see citing works

Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats

Padovan, C. M., & Guimarães, F. S. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2003.09.015 · Cited by 78 · see citing works

Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: A phantom study at 4 Tesla

Henry, M., Lauriat, T. L., Shanahan, M. E., Renshaw, P. F., & Jensen, J. E. (2010) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2010.11.003 · Cited by 73 · see citing works

Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists

Krystal, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00102-5 · Cited by 71 · see citing works

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

Javitt, D. C., & Frusciante, M. J. (1997) · Psychopharmacology · doi:10.1007/s002130050168 · Cited by 70 · see citing works

Brief Report: Acamprosate in Fragile X Syndrome

Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0988-9 · Cited by 67 · see citing works

Imaging the Glutamate System in Humans: Relevance to Drug Discovery for Schizophrenia

Stone, J. M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788957438 · Cited by 66 · see citing works

Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans

Umbricht, D., Vyssotki, D., Латанов, А. В., Nitsch, R. M., Brambilla, R., D’Adamo, P., & Lipp, H.-P. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.097 · Cited by 62 · see citing works

Effects of intravenous caffeine administered to healthy males during sleep

Lin, A. S., Uhde, T. W., Slate, S. O., & McCann, U. D. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:1 · Cited by 59 · see citing works

Genetic loss of D‐amino acid oxidase activity reverses schizophrenia‐like phenotypes in mice

Labrie, V., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. (2009) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2009.00529.x · Cited by 55 · see citing works

Functional connectivity in blood oxygenation level‐dependent and cerebral blood volume‐weighted resting state functional magnetic resonance imaging in the rat brain

Magnuson, M. E., Majeed, W., & Keilholz, S. D. (2010) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22295 · Cited by 52 · see citing works

New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors.

Papp, M., & Moryl, E. (1994) · PubMed · Cited by 51 · see citing works

Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5

Burger, C., Deschwanden, A., Ametamey, S. M., Johayem, A., Mancosu, B., Wyss, M. T., Hasler, G., & Buck, A. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2010.04.107 · Cited by 45 · see citing works

Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum

Cartmell, J., Salhoff, C. R., Perry, K. W., Monn, J. A., & Schoepp, D. D. (2000) · Brain Research · doi:10.1016/s0006-8993(00)03067-5 · Cited by 44 · see citing works

Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats1

Mickley, G. A., Schaldach, M. A., Snyder, K. J., Balogh, S. A., Len, T., Neimanis, K., Goulis, P., Hug, J., Sauchak, K., Remmers-Roeber, D. R., et al. (1998) · Physiology & Behavior · doi:10.1016/s0031-9384(98)00097-3 · Cited by 44 · see citing works

Effect of peripheral NMDA receptor blockade with ketamine on chronic myofascial pain in temporomandibular disorder patients: a randomized, double-blinded, placebo-controlled trial.

Castrillón, E., Cairns, B. E., Ernberg, M. M., Wang, K., Sessle, B. J., Arendt‐Nielsen, L., & Svensson, P. (2008) · PubMed · Cited by 41 · see citing works

A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists

Swanson, C. J., & Schoepp, D. D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.019 · Cited by 37 · see citing works

Drug-Induced Plasticity Contributing to Heightened Relapse Susceptibility: Neurochemical Changes and Augmented Reinstatement in High-Intake Rats

Madayag, A., Kau, K. S., Lobner, D., Mantsch, J. R., Wisniewski, S., & Baker, D. L. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1342-09.2010 · Cited by 35 · see citing works

Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography

Passchier, J., Gentile, G., Porter, R. A., Herdon, H. J., Salinas, C. A., Jakobsen, S., Audrain, H., Laruelle, M. A., & Gunn, R. N. (2010) · Synapse · doi:10.1002/syn.20760 · Cited by 32 · see citing works

Metabotropic glutamate receptor targets for neuropsychiatric disorders

Linden, A.-M., & Schoepp, D. D. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.10.018 · Cited by 31 · see citing works

Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.

Tsai, S. (2005) · PubMed · Cited by 31 · see citing works

Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans

Talbot, P. S., Bradley, S., Clarke, C. P., Babalola, K., Philipp, A., Brown, G. D., McMahon, A. W., & Matthews, J. C. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.182 · Cited by 28 · see citing works

PET and SPET Molecular Imaging: Focus on Serotonin System

Moresco, R. M., Matarrese, M., & Fazio, F. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778522140 · Cited by 21 · see citing works

Sensitization of rat facial cutaneous mechanoreceptors by activation of peripheral N-methyl-d-aspartate receptors

Gazerani, P., Dong, X., Wang, M., Kumar, U., & Cairns, B. E. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.018 · Cited by 20 · see citing works

5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740

Marek, G. J., Wright, R. A., & Schoepp, D. D. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.05.021 · Cited by 19 · see citing works

Murine diffusion imaging using snapshot interleaved EPI acquisition at 7 T

Guilfoyle, D. N., Gerum, S. V., & Hrabě, J. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.04.011 · Cited by 9 · see citing works

Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia

Javitt, D. C., Shelley, A.-M., Silipo, G., & Lieberman, J. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1131 · Cited by 4 · see citing works

Electrical synapses and their functional interactions with chemical synapses

Pereda, A. E. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3708 · Cited by 794 · see citing works

Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction

Ayalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., Winiger, E. A., Breier, A. F., Shekhar, A., AMDUR, R. L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.37 · Cited by 389 · see citing works

Auditory dysfunction in schizophrenia: integrating clinical and basic features

Javitt, D. C., & Sweet, R. A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4002 · Cited by 363 · see citing works

Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia

Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322 · see citing works

Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis

Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304 · see citing works

The neurobiology of depression in later-life: Clinical, neuropsychological, neuroimaging and pathophysiological features

Naismith, S. L., Norrie, L. M., Mowszowski, L., & Hickie, I. B. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.05.009 · Cited by 269 · see citing works

Add-on Treatment of Benzoate for Schizophrenia

Lane, H., Lin, C., Green, M. F., Hellemann, G., Huang, C., Chen, P., Tun, R., Chang, Y.-C., & Tsai, G. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2159 · Cited by 229 · see citing works

Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date

Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220 · see citing works

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders

Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 219 · see citing works

Posteromedial cortex glutamate and GABA predict intrinsic functional connectivity of the default mode network

Kapogiannis, D., Reiter, D. A., Willette, A. A., & Mattson, M. P. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.029 · Cited by 211 · see citing works

Intracranial Self-Stimulation to Evaluate Abuse Potential of Drugs

Negus, S., & Miller, L. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007419 · Cited by 217 · see citing works

Thinking Outside the Cleft to Understand Synaptic Activity: Contribution of the Cystine-Glutamate Antiporter (System xc−) to Normal and Pathological Glutamatergic Signaling

Bridges, R., Lutgen, V., Lobner, D., & Baker, D. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003889 · Cited by 205 · see citing works

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205 · see citing works

Transcranial magnetic stimulation in the treatment of substance addiction

Gorelick, D. A., Zangen, A., & George, M. S. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12479 · Cited by 195 · see citing works

Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction

Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161 · see citing works

Clinically Significant Drug Interactions with Newer Antidepressants

Spina, E., Trifirò, G., & Caraci, F. (2011) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160 · see citing works

Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings

Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Javitt, D. C., Lieberman, J. A., Abi‐Dargham, A., & Girgis, R. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.12.013 · Cited by 158 · see citing works

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial

Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00098-x · Cited by 148 · see citing works

Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial

Lin, C., Lin, C., Chang, Y.-C., Huang, Y.-J., Chen, P., Yang, H.-T., & Lane, H. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.006 · Cited by 138 · see citing works

The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies

Girgis, R. R., Kumar, S. S., & Brown, A. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.002 · Cited by 135 · see citing works

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

Downing, A. M., Kinon, B. J., Millen, B. A., Zhang, L., Liu, L., Ma, M., Brenner, R., Rayle, T. J., Nisenbaum, L., Zhao, F., et al. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0351-3 · Cited by 129 · see citing works

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms

Kantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123 · see citing works

Targeting of NMDA receptors in new treatments for schizophrenia

Hashimoto, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.934225 · Cited by 115 · see citing works

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression

Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113 · see citing works

Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet?

Javitt, D. C. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs100 · Cited by 108 · see citing works

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial

Javitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100 · see citing works

N-acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant

Sahasrabudhe, S. A., Terluk, M. R., & Kartha, R. V. (2023) · Antioxidants · doi:10.3390/antiox12071316 · Cited by 102 · see citing works

Hampered long-term depression and thin spine loss in the nucleus accumbens of ethanol-dependent rats

Spiga, S., Talani, G., Mulas, G., Licheri, V., Fois, G. R., Muggironi, G., Masala, N., Cannizzaro, C., Biggio, G., Sanna, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406768111 · Cited by 97 · see citing works

Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia

Kantrowitz, J. T., Hoptman, M. J., Leitman, D. I., Moreno-Ortega, M., Lehrfeld, J. M., Dias, E. C., Sehatpour, P., Laukka, P., Silipo, G. S., & Javitt, D. C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4603-14.2015 · Cited by 91 · see citing works

Impact of Ketamine on Neuronal Network Dynamics: Translational Modeling of Schizophrenia‐Relevant Deficits

Kocsis, B., Brown, R. E., McCarley, R. W., & Hajós, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12081 · Cited by 93 · see citing works

Independent and Additive Effects of Glutamic Acid and Methionine on Yeast Longevity

Wu, Z., Song, L., Liu, S., & Huang, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079319 · Cited by 89 · see citing works

Decreased mRNA expression for the two subunits of system xc−, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia

Lin, C., Lin, P., Lin, C.-Y., Lin, C., Huang, C.-H., Huang, Y.-J., & Lane, H. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.007 · Cited by 91 · see citing works

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism

Meinhardt, M. W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M. L., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2399 · Cited by 89 · see citing works

Mapping glutamate in subcortical brain structures using high‐resolution GluCEST MRI

Cai, K., Singh, A. K., Roalf, D. R., Nanga, R. P. R., Haris, M., Hariharan, H., Gur, R. C., & Reddy, R. D. (2013) · NMR in Biomedicine · doi:10.1002/nbm.2949 · Cited by 89 · see citing works

Zinc signaling and epilepsy

Doboszewska, U., Młyniec, K., Wlaź, A., Poleszak, E., Nowak, G., & Wlaź, P. (2019) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2018.08.013 · Cited by 81 · see citing works

Neurophysiological models for new treatment development in schizophrenia: early sensory approaches

Javitt, D. C. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12689 · Cited by 84 · see citing works

A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology

Javitt, D. C., Siegel, S. J., Spencer, K., Mathalon, D. H., Hong, L. E., Martı́nez, A., Ehlers, C. L., Abbas, A. I., Teichert, T., Lakatos, P., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0697-9 · Cited by 82 · see citing works

Glycine transport inhibitors in the treatment of schizophrenia

Javitt, D. C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_12 · Cited by 83 · see citing works

Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder

Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83 · see citing works

12-Week, Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive–Compulsive Disorder

Grant, P. J., Joseph, L. A., Farmer, C., Luckenbaugh, D. A., Lougee, L., Zarate, C. A., & Swedo, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.343 · Cited by 80 · see citing works

Glutamate modulates resting state activity in the perigenual anterior cingulate cortex – A combined fMRI–MRS study

Enzi, B., Duncan, N. W., Kaufmann, J., Tempelmann, C., Wiebking, C., & Northoff, G. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.039 · Cited by 73 · see citing works

Future Directions for Research in Autism Spectrum Disorders

Damiano, C. R., Mazefsky, C. A., White, S. W., & Dichter, G. S. (2014) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2014.945214 · Cited by 76 · see citing works

Perisynaptic astroglial processes: dynamic processors of neuronal information

Ghézali, G., Dallérac, G. M., & Rouach, N. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1070-3 · Cited by 69 · see citing works

Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression

Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 68 · see citing works

Convergent Findings for Abnormalities of the NF-κB Signaling Pathway in Schizophrenia

Roussos, P., Katsel, P., Davis, K. L., Giakoumaki, S. G., Siever, L. J., Bitsios, P., & Haroutunian, V. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.215 · Cited by 70 · see citing works

Chronic Cigarette Smoking in Healthy Middle-Aged Individuals Is Associated With Decreased Regional Brain N-acetylaspartate and Glutamate Levels

Durazzo, T. C., Meyerhoff, D. J., Mon, A., Abé, C., Gazdzinski, S. P., & Murray, D. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.029 · Cited by 69 · see citing works

The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders

Peyrovian, B., Rosenblat, J. D., Pan, Z., Iacobucci, M., Brietzke, E. M., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.001 · Cited by 70 · see citing works

Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia

Banerjee, A., Wang, H.-Y., Borgmann‐Winter, K. E., MacDonald, M. L., Kaprielian, H., Stucky, A., Kvasic, J., Egbujo, C. N., Ray, R., Talbot, K., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.115 · Cited by 66 · see citing works

An update on NMDA antagonists in depression

Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 65 · see citing works

Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine – a quantitative EEG study in rats

Leiser, S. C., Pehrson, A. L., Robichaud, P. J., & Sánchez, C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12782 · Cited by 63 · see citing works

BNST GluN2D-Containing NMDA Receptors Influence Anxiety- and Depressive-like Behaviors and ModulateCell-Specific Excitatory/Inhibitory Synaptic Balance

Salimando, G. J., Hyun, M., Boyt, K. M., & Winder, D. G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0270-20.2020 · Cited by 63 · see citing works

R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome

Qin, M., Huang, T., Kader, M., Krych, L., Xia, Z., Burlin, T., Zeidler, Z., Zhao, T., & Smith, C. B. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv034 · Cited by 62 · see citing works

Chronic unpredictable stress promotes cell-specific plasticity in prefrontal cortex D1 and D2 pyramidal neurons

Anderson, E. M., Gomez, D. M., Caccamise, A. J., McPhail, D., & Hearing, M. C. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100152 · Cited by 59 · see citing works

Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders

Yan, L.-Q., Shamir, A., Skirzewski, M., Leiva‐Salcedo, E., Kwon, O., Karavanova, I. D., Paredes, D., Malkesman, O., Bailey, K. R., Vullhorst, D., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.22 · Cited by 57 · see citing works

Higher Glutamate + Glutamine and Reduction of N-acetylaspartate in Posterior Cingulate According to Age Range in Patients with Cognitive Impairment and/or Pain

Fayed, N. M., Andres, E. M., Viguera, L., Modrego, P. J., & García‐Campayo, J. (2014) · Academic Radiology · doi:10.1016/j.acra.2014.04.009 · Cited by 54 · see citing works

Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies

Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 54 · see citing works

Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines

Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 56 · see citing works

Region-specific elevations of glutamate + glutamine correlate with the sensory symptoms of autism spectrum disorders

He, J. L., Oeltzschner, G., Mikkelsen, M. E., Deronda, A. C., Harris, A. D., Crocetti, D., Wodka, E. L., Mostofsky, S. H., Edden, R. A. E., & Puts, N. A. J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01525-1 · Cited by 54 · see citing works

Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment

Hung, C.-C., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189718 · Cited by 52 · see citing works

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 54 · see citing works

Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders

Thalman, C., Horta, G., Qiao, L., Endle, H., Tegeder, I., Cheng, H., Laube, G., Sigurdsson, T., Hauser, M. J., Tenzer, S., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0053-1 · Cited by 52 · see citing works

Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model

Haaf, M., Leicht, G., Ćurić, S., & Mulert, C. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180620112528 · Cited by 51 · see citing works

Molecular cause and functional impact of altered synaptic lipid signaling due to a prg‐1 gene SNP

Vogt, J., Yang, J., Mobascher, A., Cheng, J., Li, Y., Liu, X., Baumgart, J., Thalman, C., Kirischuk, S., Unichenko, P., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505677 · Cited by 49 · see citing works

Serotonin and Glutamate Interactions in Preclinical Schizophrenia Models

Shah, U. H., & González-Maeso, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00044 · Cited by 44 · see citing works

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

Mehta, M. A., Schmechtig, A., Kotoula, V., McColm, J., Jackson, K. A., Brittain, C. F., Tauscher‐Wisniewski, S., Kinon, B. J., Morrison, P. D., Pollak, T. A., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4877-9 · Cited by 47 · see citing works

A Randomized, Double-Blind, Placebo-Controlled, Trial of Lamotrigine Therapy in Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence

Brown, E. S., Sunderajan, P., Hu, L. T., Sowell, S. M., & Carmody, T. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.90 · Cited by 46 · see citing works

Mismatch negativity: A simple and useful biomarker of N-methyl-d-aspartate receptor (NMDAR)-type glutamate dysfunction in schizophrenia

Avissar, M., & Javitt, D. C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.006 · Cited by 45 · see citing works

Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression

Sepulveda-Orengo, M. T., Healey, K. L., Kim, R., Auriemma, A. C., Rojas, J. M., Woronoff, N., Hyppolite, R., & Reissner, K. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.244 · Cited by 45 · see citing works

Temporal dynamics of miRNAs in human DLPFC and its association with miRNA dysregulation in schizophrenia

Hu, Z., Gao, S., Lindberg, D. M., Panja, D., Wakabayashi, Y., Li, K., Kleinman, J. E., Zhu, J., & Li, Z. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0538-y · Cited by 44 · see citing works

N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia

Kantrowitz, J. T. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.003 · Cited by 41 · see citing works

Ketamine: The final frontier or another depressing end?

Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 40 · see citing works

Variable prenatal stress results in impairments of sustained attention and inhibitory response control in a 5-choice serial reaction time task in rats

Wilson, C. A., Schade, R., & Terry, A. V. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.040 · Cited by 40 · see citing works

Inhibition of STEP61 ameliorates deficits in mouse and hiPSC-based schizophrenia models

Xu, J., Hartley, B. J., Kurup, P. K., Phillips, A. W., Topol, A., Xu, M., Ononenyi, C., Foscue, E. P., Ho, S.-M., Baguley, T. D., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.163 · Cited by 40 · see citing works

Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma

Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073798 · Cited by 40 · see citing works

Extracellular Glutamate in the Nucleus Accumbens Is Nanomolar in Both Synaptic and Non-synaptic Compartments

Chiu, D. N., & Jahr, C. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.047 · Cited by 38 · see citing works

Effects of (R)‐(−)‐5‐methyl‐1‐nicotinoyl‐2‐pyrazoline on glutamate transporter 1 and cysteine/glutamate exchanger as well as ethanol drinking behavior in male, alcohol‐preferring rats

Aal-Aaboda, M. S., Alhaddad, H., Osowik, F. A., Nauli, S. M., & Sari, Y. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23554 · Cited by 37 · see citing works

Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia

Ballesteros, A., Summerfelt, A., Du, X., Jiang, P., Chiappelli, J., Tagamets, M., O’Donnell, P., Kochunov, P., & Hong, L. E. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.05.021 · Cited by 34 · see citing works

Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome

Pretto, D. I., Kumar, M., Cao, Z., Cunningham, C. L., Durbin-Johnson, B. P., Qi, L., Berman, R. F., Noctor, S. C., Hagerman, R. J., Pessah, I. N., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.009 · Cited by 34 · see citing works

Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors

Piniella, D., & Zafra, F. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109514 · Cited by 34 · see citing works

Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions

Zádor, F., Nagy-Grócz, G., Kékesi, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Horváth, G., Benyhe, S., & Vécsei, L. (2019) · Molecules · doi:10.3390/molecules24203709 · Cited by 32 · see citing works

Group II Metabotropic Glutamate Receptor Agonist LY379268 Regulates AMPA Receptor Trafficking in Prefrontal Cortical Neurons

Wang, M.-J., Li, Y., Snyder, M. A., Wang, H., Li, F., & Gao, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061787 · Cited by 32 · see citing works

Glutamatergic candidate genes in autism spectrum disorder: an overview

Chiocchetti, A. G., Bour, H. S., & Freitag, C. M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1161-y · Cited by 30 · see citing works

Small Molecule Screening Identifies Regulators of the Transcription Factor ΔFosB

Wang, Y., Ceseña, T. I., Ohnishi, Y. H., Burger-Caplan, R., Lam, V., Kirchhoff, P. D., Larsen, S. D., Larsen, M. J., Nestler, E. J., & Rudenko, G. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000235 · Cited by 30 · see citing works

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date

Fung, L. K., & Hardan, A. Y. (2015) · CNS Drugs · doi:10.1007/s40263-015-0252-0 · Cited by 28 · see citing works

Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy

Nagy, D., Stoiljković, M., Menniti, F. S., & Hajós, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.298 · Cited by 29 · see citing works

Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058

Sehatpour, P., Javitt, D. C., Baun, H. M. D., Carlson, M., Beloborodova, A. V., Margolin, D. H., Carlton, M. B. L., Brice, N., & Kantrowitz, J. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01170-8 · Cited by 28 · see citing works

Neuroprotective effect of penehyclidine hydrochloride on focal cerebral ischemia-reperfusion injury.

Yu, C., & Jun-ke, W. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.07.006 · Cited by 27 · see citing works

Effects of Electroconvulsive Therapy on Some Inflammatory Factors in Patients With Treatment-Resistant Schizophrenia

Kartalcı, Ş., Karabulut, A. B., Erbay, L. G., & Acar, C. (2016) · Journal of Ect · doi:10.1097/yct.0000000000000303 · Cited by 26 · see citing works

Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate–Type Glutamate Receptor Function

Kantrowitz, J. T., Swerdlow, N. R., Dunn, W., & Vinogradov, S. (2018) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.02.002 · Cited by 26 · see citing works

Increased Fear Memory and Glutamatergic Modulation in Compulsive Drinker Rats Selected by Schedule-Induced Polydipsia

Prados-Pardo, Á., Martín-González, E., Mora, S., Merchán, A., Flores, P., & Moreno, M. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00100 · Cited by 25 · see citing works

Dietary glutamate and the brain: In the footprints of a Jekyll and Hyde molecule

Onaolapo, A. Y., & Onaolapo, O. J. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.07.001 · Cited by 25 · see citing works

Hippocampal glutamatergic/NMDA receptor functioning in bipolar disorder: A study combining mismatch negativity and proton magnetic resonance spectroscopy

Chitty, K. M., Lagopoulos, J., Hickie, I. B., & Hermens, D. F. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.05.002 · Cited by 24 · see citing works

Chronic Effects of Cannabis Use on the Auditory Mismatch Negativity

Greenwood, L., Broyd, S. J., Croft, R. J., Todd, J., Michie, P. T., Johnstone, S. J., Murray, R. M., & Solowij, N. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.05.035 · Cited by 24 · see citing works

Autoimmune-induced glutamatergic receptor dysfunctions: Conceptual and psychiatric practice implications

Rosenthal-Simons, A., Durrant, A. R., & Heresco‐Levy, U. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.008 · Cited by 24 · see citing works

Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway

Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01086-1 · Cited by 22 · see citing works

Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats

Alhaddad, H., Wong, W., Abou-Gharbia, M. A., Childers, W. E., Melenski, E., Bell, R. L., & Sari, Y. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001147 · Cited by 22 · see citing works

Maturation- and sex-sensitive depression of hippocampal excitatory transmission in a rat schizophrenia model

Patrich, E., Piontkewitz, Y., Peretz, A. S., Weiner, I., & Attali, B. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.08.021 · Cited by 22 · see citing works

The trading zone of autism genetics: Examining the intersection of genomic and psychiatric classification

Navon, D., & Eyal, G. (2014) · BioSocieties · doi:10.1057/biosoc.2014.18 · Cited by 21 · see citing works

In Situ Electrically Resettable Field‐Effect Transistor Biosensors for Continuous and Multiplexed Neurotransmitter Detection

Xiao, B., Li, T., Cao, X., Zhang, Y., He, J., Xiao, M., & Zhang, Z. (2025) · Advanced Science · doi:10.1002/advs.202504497 · Cited by 21 · see citing works

Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors

Harvey, B. D., Siok, C. J., Kiss, T., Volfson, D., Grimwood, S., Shaffer, C. L., & Hajós, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.020 · Cited by 21 · see citing works

Role of Central Glutamatergic Neurotransmission in the Pathogenesis of Psychiatric and Behavioral Disorders

Wang, S., & Yang, T. (2005) · Drug News & Perspectives · doi:10.1358/dnp.2005.18.9.953668 · Cited by 17 · see citing works

Glutamatergic Dysregulation in Depression, Schizophrenia, and Addiction: Mechanisms and Therapeutic Strategies

Shi, W., & Bai, J. (2026) · Actas Españolas de Psiquiatría · doi:10.62641/aep.2307

Glutamatergic Pathways

Smith, Y. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-852-6_3 · Cited by 1 · see citing works

Translational medicine of the glutamate AMPA receptor

Miyazaki, T., Hiroki, A. B. E., Uchida, H., & Takahashi, T. (2021) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.97.001 · Cited by 12 · see citing works

Glutamate as a therapeutic target in psychiatric disorders

Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524 · see citing works